Fina Biosolutions

Executive Summary

Fina Biosolutions is a private U.S.-based company founded in 2006 and headquartered in Rockville, Maryland, specializing in conjugate vaccine development and manufacturing services. The company is recognized as a leading expert in bioconjugation and provides a range of protein services, with a particular focus on the carrier protein CRM197, which is widely used in pediatric vaccines. Fina Biosolutions assists vaccine developers and manufacturers in creating affordable conjugate vaccines through its technical expertise and service offerings. Although the company has an 'Approved' stage designation, indicating it has at least one approved product or technology, detailed financial information, pipeline details, and commercial product data are not publicly available. The company operates in the antibodies category and serves the broader biotechnology and pharmaceutical sectors. Fina Biosolutions' business model centers on enabling partners to accelerate vaccine development and reduce costs, leveraging its proprietary conjugation platforms and carrier protein supply. While the company has limited public visibility, its niche expertise positions it as a valuable partner in the conjugate vaccine space, particularly for emerging markets seeking affordable vaccination solutions.

Upcoming Catalysts (preview)

• Q4 2026New Partnership or Licensing Deal for CRM197 Supply65% success
• 2027Announcement of Expanded Manufacturing Capacity50% success
• H2 2026Client Vaccine Candidate Featuring Fina's Conjugation Technology Achieves Phase 2/3 Readout40% success